公开(公告)号：US20220162191A1

公开(公告)日：2022-05-26

申请号：US17436885

申请日：2020-03-06

Applicant: LEO PHARMA A/S

Inventor： Xifu LIANG ,  Kevin Neil DACK ,  Peter ANDERSEN ,  Morten Dahl SØRENSEN ,  Mark ANDREWS ,  Alan Stuart JESSIMAN

IPC: C07D403/12 ,  C07D401/14 ,  C07D401/12 ,  C07D413/14 ,  C07D471/08 ,  C07D417/14 ,  C07D491/107 ,  C07D491/048 ,  C07D403/14 ,  C07D405/14

Abstract: The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

公开(公告)号：US20210079012A1

公开(公告)日：2021-03-18

申请号：US16772615

申请日：2018-12-14

Applicant: LEO Pharma A/S

Inventor： Mark ANDREWS ,  Daniel Rodriguez GREVE ,  Bjarne NØRREMARK

IPC: C07D495/04

Abstract: The present invention relates to novel substituted azetidine dihydrothienopyridines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I)

公开(公告)号：US20230250079A1

公开(公告)日：2023-08-10

申请号：US18001464

申请日：2021-06-10

Applicant: LEO PHARMA A/S

Inventor： Mark ANDREWS ,  Morten Dahl SØRENSEN ,  Mogens LARSEN ,  Nicolas DEVAUX ,  Vinicius BARROS RIBEIRO DA SILVA ,  Quentin PERRON ,  Xifu LIANG ,  Jimmi Gerner SEIZBERG

IPC: C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D403/12

CPC classification number: C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D403/12

Abstract: The present disclosure relates to a compound according to formula I




and pharmaceutically acceptable salts, hydrates, or solvates thereof. The disclosure further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

公开(公告)号：US20230227435A1

公开(公告)日：2023-07-20

申请号：US18002080

申请日：2021-06-17

Applicant: LEO PHARMA A/S

Inventor： Mark ANDREWS ,  Kevin Neil DACK ,  Jimmi Gerner SEITZBERG ,  Peter ANDERSEN

IPC: C07D403/12 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D405/14

CPC classification number: C07D403/12 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D405/14

Abstract: The present disclosure relates to compounds according to formula I






and pharmaceutically acceptable salts, hydrates, or solvates thereof. The disclosure further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

公开(公告)号：US20240208938A1

公开(公告)日：2024-06-27

申请号：US18526149

申请日：2023-12-01

Applicant: LEO Pharma A/S

Inventor： Mark ANDREWS ,  Mogens LARSEN ,  Alan JESSIMAN ,  Patrick JOHNSON ,  Kevin Neil DACK

IPC: C07D401/14

CPC classification number: C07D401/14

Abstract: The present invention relates to a compound according to formula (I)




and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g., dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

公开(公告)号：US20210070769A1

公开(公告)日：2021-03-11

申请号：US16772428

申请日：2018-12-14

Applicant: LEO Pharma A/S

Inventor： Mark ANDREWS ,  Daniel Rodriguez GREVE ,  Jens LARSEN

IPC: C07D495/04

Abstract: The present invention relates to novel substituted azetidine dihydrothienopyrimidines with phosphodiesterase inhibitory activity, and to their use in therapy, and to pharmaceutical compositions comprising the compounds and to methods of treating diseases with the compounds (I).